Business Context and Reporting Period
Company: MiNK Therapeutics, Inc. (INKT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: MiNK is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company operates as a single segment and is classified as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(5,870,570) | $(7,004,448) | N/A |
| Operating Loss | $(6,098,681) | $(6,753,083) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $8,806,977 |
| Net Cash Used in Operating Activities | $(3,815,409) | $(2,910,094) | N/A |
| Total Assets | N/A | N/A | $9,615,242 |
| Total Liabilities | N/A | N/A | $23,643,538 |
| Stockholders' Deficit | N/A | N/A | $(14,028,296) |
| Accumulated Deficit | N/A | N/A | $(162,546,564) |
Note: The company has no revenue. Total liabilities include $16.1 million due to related parties (Agenus) which is not currently due for repayment.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $1.13 million (16%) for the six months ended June 30, 2026, compared to the same period in 2025. This was driven by a decrease in General and Administrative (G&A) expenses and the absence of fair value adjustments on related party notes.
- Expense Management: G&A expenses decreased 4% year-over-year to $3.0 million, primarily due to reduced share-based compensation and professional fees. Research and Development (R&D) expenses remained flat at approximately $3.1 million.
- Debt Repayment: The company repaid a $5.0 million convertible promissory note to Agenus in full in January 2026. Consequently, the "Related party note" liability was eliminated from the balance sheet, though a significant "Due to related parties" balance of $16.1 million remains for allocated services.
- Equity Financing: The company raised approximately $4.4 million in net proceeds from the sale of 313,478 shares of common stock under its At Market Issuance Sales Agreement during the six-month period.
- Liquidity Position: Cash and cash equivalents decreased by $4.6 million from $13.4 million at year-end 2025 to $8.8 million at June 30, 2026, reflecting operating cash burn partially offset by equity proceeds.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has disclosed that substantial doubt exists regarding the company's ability to continue as a going concern for one year following the filing date. The company expects to continue incurring operating losses and requires additional funding to sustain operations.
- Funding Strategy: Potential sources of future funding include strategic partnerships, out-licensing, non-dilutive financing (grants), and equity or debt offerings. Approximately $30.6 million remains available under the current At Market Sales Agreement.
- Clinical Progress:
- agenT-797: The lead native iNKT cell therapy is in Phase 2 trials for severe pneumonia/acute respiratory failure (AHRF) and solid tumors. Data presented in 2026 showed durable clinical activity in refractory cancers and immune reprogramming benefits in respiratory conditions.
- Pipeline: Preclinical development continues for engineered programs MiNK-215 (FAP-CAR-iNKT) and MiNK-413 (BCMA-CAR-iNKT).
- Risks: Key risks include the inability to secure additional financing, delays in clinical trials, regulatory hurdles, and the inherent uncertainty of developing novel cell therapies. The company relies on Agenus for certain administrative and R&D services.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.8 million cash balance against projected burn rates and the timeline for anticipated funding.
- Related Party Obligations: Review the terms of the $16.1 million "Due to related parties" balance owed to Agenus to confirm repayment terms and interest implications.
- ATM Utilization: Monitor the remaining $30.6 million capacity under the At Market Sales Agreement and the pricing of future share issuances.
- Clinical Milestones: Track enrollment and data readouts for the Phase 2 AHRF trial and the investigator-sponsored trial for GvHD prevention.
- Going Concern Status: Assess the likelihood of securing the "additional funding" required to resolve the substantial doubt disclosure.